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Summary The pharmacokinetics of the hypoxic radio-sensitizer nimorazole were studied in 19 individuals
after single oral doses of between 0.5-3.5 g. HPLC measurements showed, after a rapid absorption, a linear
relationship between peak plasma concentration and given dose. Mean elimination half life was 3.1 h. A
tendency to a dose-dependent variation in the apparent volume of distribution, total body clearance and
elimination half life suggest non-linear pharmacokinetics of nimorazole. Tumour concentrations measured in 5
patients gave tumour/plasma ratios between 0.8-1.3. No toxicity was observed. The results indicate that
nimorazole may have potential as a clinically useful hypoxic radiosensitizer.
Recent studies in experimental tumours in vivo
suggest that nimorazole (1-(N-p-ethyl-morpholine)-
5-nitro-imidazole) may possess hypoxic cell
radiosensitizing properties similar to that of
misonidazole (MISO) when given in moderate doses
(Overgaard et al., 1982b). At tumour concentrations
of 50 gg- 1 both drugs were found to yield
enhancement ratios of 1.4 in a C3H mammary
carcinoma (Overgaard et al., 1982b). Clinical studies
of plasma and tumour concentrations indicate that
an equivalent dose level in humans would require
- 1.5-2.0gm -2 MISO on the likely assumption
that a tumour-plasma ratio of about unity can be
achieved (Ash & Schmidt, 1980; Dische, 1982; Rich
et al., 1981). Such a dose cannot be given daily in
conjunction with conventional radiation
fractionation schedules due to excessive dose-
limiting toxicity, primarily expressed as peripheral
neuropathy (Dische et al., 1978; Kogelnik 1980;
Phillips et al., 1981). Thus, accumulated doses > 11-
12gm-2 MISO over a 4-week period carry a high
risk of unacceptable side effects (Dische et al., 1978,
1979; Kogelnik, 1980; Overgaard et al., 1982a;
Phillips et al., 1981; Urtasun et al., 1982).
Clinical experience with nimorazole as an
antimicrobial agent indicates that the drug is
considerably less toxic than MISO. Total doses of
25g in 10 days have easily been administrated to
both adults and children, the only side effect being
mild gastrointestinal disturbances with nausea and
occasional vomiting. This toxicity was observed in
5-25% of patients, was found to be dose-
independent and often transitory and could
otherwise be controlled with antiemetics
(Arrubarrena et al., 1971; Cue & Traslosheros, 1969;
Daza, 1973; Garcia et al., 1975; Oliva et al., 1972).
Experience from large animal toxicity studies
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(Farmitalia, Carlo Erba, unpublished observations)
suggests that nimorazole may be even better
tolerated than metronidazole (Flagyl) which itself
can be administrated in daily doses of 6gm-2 up to
a total of 100g, although such high doses may be
associated with significant gastrointestinal toxicity
and some central and peripheral neuropathy (Kapp
et al., 1982; Karim, 1978; Urtasun et al., 1975, 1982).
If the lack of significant toxicity is confirmed, it may
be possible to give nimorazole in conjunction with
conventional daily radiation fractionation schedules
at a dose level which may enhance the radiation
response of hypoxic cells by a factor of - 1.4.
Therefore, nimorazole represents a potentially
attractive compound for hypoxic radiosensitization
in clinical radiotherapy.
Although there is information about the tolerance
and metabolism of single dose nimorazole (Giralsi
et al., 1971), details of the pharmacokinetic
properties with regard to absorption, elimination
and plasma and tumour concentrations are very
limited. The present study was therefore performed
with the aim of obtaining further information about
the pharmacokinetics of nimorazole given in single
doses between 0.5-3.5g.
Materials and methods
Pharmacokinetic measurements were performed in
informed volunteers of whom 11 were patients
receiving radiotherapy for malignant tumours, and
8 were healthy male scientists (Table I). All subjects
had normal hepatic and renal function.
Nimorazole was supplied by Farmitalia,
Carlo Erba in tablets of 500mg which were given in
single oral doses, as indicated in Table II. The drug
was normally given with, or shortly after, a light
breakfast. Serial venous blood samples were usually
collected at intervals of 15-30min over the first 2-
3 h and then at 4, 6-8 and 24h after administration.
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Table I Details of subjects in the study
Surface
Age Weight Height area
Subject Sex (yr) (kg) (cm) (m2) Diagnosis
1 M 35 70 181 1.9 Healthy
2 M 29 67 177 1.9 Healthy
3 F 61 59 165 1.6 Breast carcinoma
4 M 36 90 196 2.3 Healthy
5 M 39 71 176 1.9 Healthy
6 M 32 79 185 2.1 Healthy
7 M 49 70 187 2.1 Healthy
8 F 65 65 154 1.6 Rectal carcinoma
9 M 63 49 168 1.5 Epidermoid carcinoma
ofthe pinna
10 M 65 101 176 2.2 Epidermoid carcinoma
of the anus
11 M 39 70 172 1.8 Healthy
12 M 76 55 170 1.6 Prostate carcinoma
13 M 50 55 173 1.6 Epidermoid carcinoma
of the larynx
14 M 25 76 189 2.1 Healthy
15 F 72 75 163 1.8 Lymphoma
16 M 58 64 170 1.7 Myeloma
17 M 71 80 177 1.9 Lymphoma
18 F 56 64 170 1.7 Malignant melanoma
19 M 30 73 178 2.0 Malignant melanoma
No specific restrictions were given with regard to
drinking or eating in the test period. In subjects
receiving multiple doses, these were given with at
least 4 weeks' interval.
Measurement ofdrug
Plasma and tumour concentrations of nimorazole
were measured by high pressure liquid
chromatography (HPLC). The venous blood was
collected in heparinized tubes, centrifuged at 3,000g
for 10min after which the plasma was removed.
Methanol (250 il) was added to 25p1 plasma
together with naproxen as internal standard. After
Vortex mixing the samples were allowed to rest for
10min before centrifugation at 3,000g for 5min.
The supernatant was collected in a Hamilton
syringe and used for' HPLC determination. A
Waters high performance liquid chromatography
system was used composed of 2 model 6000A
pumps, a model 660 solvent flow programmer, a
model U6K injector, a model 440 fixed wavelength
UV detector having an 8 u1 flow through cell. The
system was connected to an Omniscribe dual
channel chart recorder. Reversed phase HPLC
measurements were performed by injecting 25il of
the sample onto a nucleosil IOt C18 column using
60% methanol in 20mM phosphate buffer, pH 6.5
as mobile phase at a flow of 2mlmin-'. The UV-
absorption was measured at 313 nm (Figure 1).
Tumour concentrations were measured in tissues
obtained by biopsy. After weighing a known
amount of internal standard was added together
with methanol to a 5-fold increase in volume. After
mixing with a rotating knife, the sample was
centrifuged at 3,000g for 10min. The supernatant
was removed and the solvent evaporated at 37°C
under a stream of dry nitrogen. Dried residue was
redissolved in 500 i1 methanol and after Vortex
agitation, injected onto the HPLC column and
estimated similar to the plasma samples. All plasma
and tumour measurements were performed in
duplicate, and the daily standard calibration curve
was performed using different but known
concentrations of drugs in plasma.
Pharmacokinetic calculations
The plasma pharmacokinetic parameters are
described on the assumption of first order
absorption and elimination kinetics. The elimination
rate constant ke is determined during the
elimination phase by least square regression
calculation of the slope of a log-linear plot of
nimorazole dose versus time. The elimination half
life is then given by In2/ke. The area under the
curve (AUCO - .) which gives an expression of the
concentration x time exposure to the drug was
calculated by the trapezoidal rule from time 0 to
time t (usually 6h). The remaining area wasPHARMACOKINETIC PROPERTIES OF NIMORAZOLE 29
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Figure 1 HPLC pattern of plasma containing
79 pgml -' nimorazole extracted with methanol-
containing naproxen as internal standard.
calculated by the formula Ct/ke, where C, is the
plasma concentration at time t. The apparent
volume of distribution (Vd) was estimated as D/AUC
where D is the total dose in g. Plasma clearance
was calculated as D/ke*AUC. Under the
assumption that the kinetics follow a two-
compartment one way model, a rough estimate of
the absorption rate (ka) is obtained by the formula
AUC=Co/ke-Co/ka, where C0 is the dose at time
0 obtained by extrapolation of the log-linear
elimination curve. Similarly, the absorption half life
was estimated as ln 2/ka.
Nimorazole was well tolerated, and with the
exception of slight nausea in one subject (2.5 g
dose), no acute or chronic side effects have been
recorded.
Plasma pharmacokinetic parameters obtained
after single doses from 0.5-3.5g are shown in Table
II and typical plasma profiles are illustrated in
Figure 2. Nimorazole is easily absorbed after oral
administration with a mean absorption half life of
24min +2 (s.e.). The absorption appears to be
dose-independent. Peak plasma concentrations are
reached between 35 and 125min after intake
(median 90min). The peak plasma concentration
was linear-linear related to the given dose in g, and
this correlation was further improved if the dose
was expressed in g m 2 or better as mgkg- I
(Figure 3). Thus, the peak plasma concentration
was found to be 20.0+2.0 (s.e.), 38.0+2.8 and 1.30
±0.10pgml-1, respectively when calculated per g,
g m 2 and mgkg-1, respectively. Plasma
elimination occurred with a half life ranging from
2.0-4.6h with a mean of 3.1 +0.1. The elimination
half life was found to be one of the most variable
parameters but was not significantly altered as a
function of dose (Figure 5).
The exposure to the drug calculated as the area
under the curve (AUC) was also found to be dose
related, although to a smaller extent than the peak
plasma concentration due to the variations in drug
elimination. However, there was a well-established
linear-linear relationship between AUC and given
dose, especially when expressed as mgkg-1 (Figure
4).
The distribution of the drug estimated as the
apparent volume of distribution (Vd) had a mean
value of 0.79+0.041kg- 1. Although not statistically
significant there appeared to be a trend towards a
lower volume of distribution with increasing dose
(Figure 5). A similar tendency was seen for the total
body clearance (mean 218+191min-1) which also
appeared, although not statistically significant, to
become smaller with increasing given dose. Thus,
from the present data there are suggestions that
certain parameters follow non-linear
pharmacokinetics. This suggestion gets further
support when analysing two subjects (1 and 4) in
which multiple dose levels have been measured.
Both showed an increasing elimination half life and
a decrease in total body clearance and Vd with
increasing given doses (Table II). It is therefore
likely that the pharmacokinetics may be non-linear
on an individual basis, but that this non-linearity is
so small that it requires a larger investigation before
it becomes generally apparent.
From the point of hypoxic radiosensitizing effect,
tumour rather than the plasma concentration is the
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Table II Summary ofplasma pharmacokinetic parameters
Absorption Elimination Plasma
Dose Peak conc. Reaction halflife halflife clearance Vd AUC0o
Subject g gm-2 mgkg-1 (jgml-1) (min) (min) (h) (mlmin1) (lkg-') (lugmUl1hr)
1 0.5 0.3 7.1 5.9 60 22 2.6 320 1.03 26
2 0.5 0.3 7.5 7.0 60 22 2.5 278 0.90 30
3 1.0 0.6 16.9 14.7 120 49 3.7 183 0.99 91
4 1.0 0.4 11.1 10.0 65 20 2.4 417 0.96 40
5 1.5 0.8 21.1 23.5 35 11 2.9 240 0.85 104
6 1.5 0.7 19.0 29.2 100 23 2.7 187 0.55 134
1 1.5 0.8 21.4 24.6 60 44 2.8 248 0.86 101
7 1.5 0.7 21.4 19.0 100 46 2.0 397 0.98 63
8 1.5 0.9 23.1 25.7 90 31 3.2 182 0.77 138
4 2.0 0.8 22.8 22.4 120 25 3.1 273 0.80 122
9 2.0 1.3 40.0 49.8 60 18 3.5 113 0.69 293
10 2.0 0.9 19.8 31.0 60 16 2.9 233 0.58 143
11 2.0 1.1 28.6 39.1 100 24 4.6 108 0.62 310
12 2.0 1.3 35.7 56.9 60 13 2.6 140 0.57 238
13 2.0 1.2 36.4 44.2 90 12 3.6 125 0.71 266
14 2.5 1.2 32.9 34.4 60 17 3.5 210 0.84 199
15 2.5 1.3 33.3 25.0 60 23 3.0 372 1.29 109
2 2.5 1.3 37.3 50.5 60 8 3.5 145 0.66 285
16 3.0 1.7 46.9 69.5 90 32 4.2 107 0.61 469
1 3.0 1.6 42.9 49.4 120 25 3.2 168 0.67 296
4 3.0 1.3 33.3 41.0 125 41 3.7 192 0.69 262
12 3.5 2.2 63.6 79.3 45 14 2.9 155 0.71 376
Dose of nimorazole
80 g g m-2 mg kg-1
d 3.5 2.2 63.6
o 2.5 1.3 37.3
* 1.5 0.7 19.0
0 0.5 0.3 7.1
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Figure 2 Typical plasma concentration profiles of nimorazole given in different doses.PHARMACOKINETIC PROPERTIES OF NIMORAZOLE 31
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critical tissue. Tumour biopsies were obtained from
5 patients 2h after intake of the drug (Table III).
The tumour/plasma ratios ranged from 0.84-1.30
indicating that the same concentration levels can be
achieved in tumour and plasma. In a part of the
tumour sample from subject 8 a low tumour
concentration was obtained, but this sample
consisted of necrotic fluid and in more solid tumour
tissue from the same metastasis a considerably
higher concentration was found.
Early in the study nimorazole was tested for its
potential clinical radiosensitizing ability. The data
in Figure 6 show the effect of nimorazole on the
initial radiation response in metastases from a
malignant melanoma. In the same patient, different
cutaneous metastases were treated with single doses
of radiation, either alone or 4h after a dose of
nimorazole (51mgkg-1). This 4h interval between
drug intake and radiation was because the
treatment was performed prior to these
c
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Figure 5 Scatter diagram showing the relationship
between dose of nimorazole in mgkg-1 and the
apparent volume of distribution (Vd), total body
clearance and elimination half life.
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Table III Comparable plasma and tumour concentrations
Time after Concentration
Dose intake Plasma Tumour Tumour/plasma
Subject (mgkg-1) (min) (pgml 1) (,igg 1) ratio Biopsy
10 19.8 135 18.7 19.8 1.06 Local anal
recurrence
8 23.1 120 20.7 17.5 0.85 Subcutaneous
gluteal
metastasis
8 23.1 120 20.7 <2 <0.10 Same, necrotic
fluid
17 25.0 100 14.2 14.1 0.99 Subcutaneous
chestwall
metastasis
18 31.3 120 17.0 14.3 0.84 Cutaneous
melanoma
on leg
9 40.0 120 32.2 41.9 1.30 Neck node
100 11.0 Gy6.7 Gy
e50 -8.0
Gy
06 .X
o 10 20 0 10 20
Time (d) after treatment
Figure 6 Initial regression of cutaneous metastases
from malignant melanoma treated with different single
doses of radiation alone or radiation 4h after a dose of
51 mgkg1 nimorazole. (Subject 19).
pharmacokinetic studies and used a schedule similar
to that applied to MISO. Presuming that the dose
response pattern for initial tumour regressing
reflects the radiation response, nimorazole seems to
result in an enhanced radiation response. Naturally
such an assumption is subject to severe limitations,
but is supported by the apparent dose-response
relationship. No obvious differences in acute skin
reaction at identical radiation dose levels was noted;
however, the patient died 2 months after treatment
due to disseminated disease.
Discussion
The plasma pharmacokinetic analysis of nimorazole
indicates that the drug is readily absorbed and that
concentrations >50/,gml-1 can be achieved in the
plasma after doses of 1.5gm-2. With all the
reservations inherent in attempts to extrapolate
from experimental data to the clinical situation, it is
reasonable to assume that such a concentration, if
attainable in the tumour, may result in substantial
hypoxic cell radiosensitization (Overgaard et al.,
1982b).
The elimination of nimorazole occurs with a half
life of - 3h compared to 10-12h for MISO. In
spite of that, the peak plasma concentrations
observed in the present study are very similar to
those obtained with comparable doses of oral
MISO and metronidazole (Deutsch et al., 1975;
Dische et al., 1979; Kogelnik, 1980; Phillips et al.,
1981; Schwade et al., 1981; Workman, 1980).
However, exposure to the drug expressed by the
AUC was, at equivalent doses, only about one third
of the AUC values for MISO (Overgaard et al.,
unpublished observations), and this may account
for the low toxicity. Thus, no neurological
disturbances have been observed, the only side
effect being gastrointestinal, and at a level which
can be controlled by antiemetic therapy.
In addition, the tumour plasma ratios were
similar to those observed with MISO (Rich et al.,
1981), and it is likely that the concentration in
viable tumour tissue will be of the same magnitude
as the plasma level. The low level found in necrotic
tissue in one tumour is also in agreement with morePHARMACOKINETIC PROPERTIES OF NIMORAZOLE 33
detailed data from tumours exposed to MISO (Rich
et al., 1981). The apparently similar tumour/plasma
ratios of MISO and nimorazole despite differences
in elimination half life were an expected observation
(Workman, 1980). It is therefore likely that tumour
concentrations corresponding to those which result
in an enhancement ratio of 1.4 in an experimental
tumour treated with single doses of nimorazole can
be achieved in the clinical situation. Furthermore,
the experimental results indicate that the dose-
response relationship for the radiosensitizing effect
of nimorazole is minimal once a threshold has been
reached (Overgaard et al., 1982b). It is anticipated
that this threshold level can be achieved clinically,
since nimorazole appears to be no more toxic than
metronidazole (Flagyl). Thus, it is expected that
nimorazole could be given in daily doses of
-1.5gm-2 over 5-6 weeks which will allow the
drug to be used in conventional radiation
fractionation schedules. An on-going phase 1
clinical study has shown that 2g daily for 4 weeks
can be tolerated without side effects other than
moderate and acceptable nausea (Timothy et al.,
unpublished observations).
The tendency to non-linear pharmacokinetics
observed in the present study is not unexpected
since similar patterns have been observed for both
MISO and nimorazole in mice (Workman, 1979,
1980). However, the extent of the observed non-
linearity is small and within the variations
otherwise observed among the investigated subjects.
It may therefore have no practical implication for
the use of nimorazole as a hypoxic radiosensitizer.
Nimorazole is almost completely metabolized and
two metabolites have been characterized (Giraldi,
1971; Workman, 1980). In the present study these
have not been analysed, but preliminary studies
suggest a lower hypoxic radiosensitizing ability
than nimorazole and these may therefore not
contribute significantly to the overall hypoxic
radiosensitization (Smithen & Hardy, 1982).
The present pharmacokinetic data together with
the experimental tumour studies (Overgaard et al.,
1982b) give promise of a hypoxic radiosensitizer
that may be used clinically in doses which, when
given in normal radiation fraction schemes, may
result in higher enhancement ratios than any
currently available sensitizer in clinical use, and
with a low toxicity. Therefore, nimorazole deserves
a high priority among those hypoxic cell
radiosensitizers which are currently being
considered as candidates for clinical evaluation.
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